JP2023506593A5 - - Google Patents
Info
- Publication number
- JP2023506593A5 JP2023506593A5 JP2022552323A JP2022552323A JP2023506593A5 JP 2023506593 A5 JP2023506593 A5 JP 2023506593A5 JP 2022552323 A JP2022552323 A JP 2022552323A JP 2022552323 A JP2022552323 A JP 2022552323A JP 2023506593 A5 JP2023506593 A5 JP 2023506593A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024078761A JP2024097985A (ja) | 2020-03-06 | 2024-05-14 | 抗ｇｉｔｒ抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986494P | 2020-03-06 | 2020-03-06 | |
| US62/986,494 | 2020-03-06 | ||
| PCT/US2021/021109 WO2021178814A1 (en) | 2020-03-06 | 2021-03-05 | Anti-gitr antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024078761A Division JP2024097985A (ja) | 2020-03-06 | 2024-05-14 | 抗ｇｉｔｒ抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506593A JP2023506593A (ja) | 2023-02-16 |
| JP2023506593A5 true JP2023506593A5 (https=) | 2024-03-05 |
| JP7566923B2 JP7566923B2 (ja) | 2024-10-15 |
Family
ID=75223517
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552323A Active JP7566923B2 (ja) | 2020-03-06 | 2021-03-05 | 抗ｇｉｔｒ抗体およびその使用 |
| JP2024078761A Withdrawn JP2024097985A (ja) | 2020-03-06 | 2024-05-14 | 抗ｇｉｔｒ抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024078761A Withdrawn JP2024097985A (ja) | 2020-03-06 | 2024-05-14 | 抗ｇｉｔｒ抗体およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11787867B2 (https=) |
| EP (1) | EP4114859A1 (https=) |
| JP (2) | JP7566923B2 (https=) |
| KR (1) | KR20220151172A (https=) |
| CN (1) | CN115244084A (https=) |
| AU (1) | AU2021232041A1 (https=) |
| BR (1) | BR112022017156A2 (https=) |
| CA (1) | CA3168173A1 (https=) |
| CL (1) | CL2022002404A1 (https=) |
| CO (1) | CO2022012467A2 (https=) |
| IL (1) | IL296043A (https=) |
| MX (2) | MX2022010910A (https=) |
| PH (1) | PH12022552295A1 (https=) |
| WO (1) | WO2021178814A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4218787A3 (en) * | 2019-08-20 | 2023-12-20 | Nuritas Limited | Peptides for treating muscle atrophy |
| US11787867B2 (en) | 2020-03-06 | 2023-10-17 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| ES2308787T3 (es) | 1996-08-16 | 2008-12-01 | Schering Corporation | Antigenos de superficie de celular de mamiferos; reactivos relacionados. |
| US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| US6503184B1 (en) | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| WO1999025834A1 (en) | 1997-11-18 | 1999-05-27 | Genentech, Inc. | Dna19355 polypeptide, a tumor necrosis factor homolog |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| EP1462114A1 (en) | 2003-03-28 | 2004-09-29 | Universiteit Utrecht Holding B.V. | Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18) |
| US7618632B2 (en) | 2003-05-23 | 2009-11-17 | Wyeth | Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies |
| US20060099171A1 (en) | 2004-11-05 | 2006-05-11 | Masahide Tone | Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| WO2007084775A2 (en) | 2006-01-20 | 2007-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| WO2013051718A1 (ja) | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | キメラ抗原受容体 |
| KR101566539B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SI3148579T1 (sl) | 2014-05-28 | 2021-07-30 | Agenus Inc. | Proti GITR antitelesa in postopki z njihovo uporabo |
| PE20170441A1 (es) | 2014-06-06 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| ES2808153T3 (es) | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Terapia de combinación para tratamiento de enfermedad |
| CN108290936B (zh) * | 2015-08-14 | 2022-07-12 | 默沙东公司 | 抗tigit抗体 |
| CN109563170B (zh) | 2016-06-10 | 2023-10-13 | 瑞泽恩制药公司 | 抗gitr抗体及其用途 |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| CN110168105B (zh) * | 2016-12-09 | 2024-05-24 | 瑞泽恩制药公司 | 用于对t细胞受体进行测序的系统和方法及其用途 |
| US11787867B2 (en) | 2020-03-06 | 2023-10-17 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
-
2021
- 2021-03-05 US US17/193,586 patent/US11787867B2/en active Active
- 2021-03-05 IL IL296043A patent/IL296043A/en unknown
- 2021-03-05 CA CA3168173A patent/CA3168173A1/en active Pending
- 2021-03-05 CN CN202180019162.8A patent/CN115244084A/zh active Pending
- 2021-03-05 AU AU2021232041A patent/AU2021232041A1/en active Pending
- 2021-03-05 MX MX2022010910A patent/MX2022010910A/es unknown
- 2021-03-05 WO PCT/US2021/021109 patent/WO2021178814A1/en not_active Ceased
- 2021-03-05 EP EP21714587.9A patent/EP4114859A1/en active Pending
- 2021-03-05 JP JP2022552323A patent/JP7566923B2/ja active Active
- 2021-03-05 BR BR112022017156A patent/BR112022017156A2/pt unknown
- 2021-03-05 KR KR1020227032554A patent/KR20220151172A/ko active Pending
- 2021-03-05 PH PH1/2022/552295A patent/PH12022552295A1/en unknown
-
2022
- 2022-08-31 CO CONC2022/0012467A patent/CO2022012467A2/es unknown
- 2022-09-02 MX MX2023012739A patent/MX2023012739A/es unknown
- 2022-09-05 CL CL2022002404A patent/CL2022002404A1/es unknown
-
2023
- 2023-09-06 US US18/461,760 patent/US12331127B2/en active Active
-
2024
- 2024-05-14 JP JP2024078761A patent/JP2024097985A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7671377B2 (ja) | 抗メソテリン抗体 | |
| TWI714864B (zh) | 檢查點抑制劑雙特異性抗體 | |
| JP6947639B2 (ja) | 二重特異性四価抗体並びにその製作及び使用方法 | |
| US12384853B2 (en) | Anti-HER2/PD1 bispecific antibody | |
| JP2021531764A5 (https=) | ||
| JP2022515318A5 (https=) | ||
| JP2019521098A5 (https=) | ||
| JP2021518103A5 (https=) | ||
| JP2019524693A5 (https=) | ||
| JP2018503365A5 (https=) | ||
| JP2020516240A5 (https=) | ||
| JP2019500891A5 (https=) | ||
| RU2017118225A (ru) | Антитела к PD-1 и способы их применения | |
| JP2019521645A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2020514310A5 (https=) | ||
| JP2017535257A5 (https=) | ||
| JP2018523493A5 (https=) | ||
| JP2023543152A5 (https=) | ||
| JP2019529373A5 (ja) | 抗Ｔｉｍ−３抗体 | |
| RU2017142008A (ru) | Новые полипептиды | |
| AU2020363041B2 (en) | Antibodies against the poliovirus receptor (PVR) and uses thereof | |
| CN117946277A (zh) | 多特异性抗体及其制备和使用方法 | |
| CN114514244A (zh) | T细胞活化抗体 | |
| JP2023506593A5 (https=) |